CFO Horn Sells 7,743 Shares of Seer Inc. Amidsteadily Increasing Holdings, CEO Holds 3.35M Shares in Strategic Balancing Act

Insider Activity at Seer Inc. Signals Strategic Realignment

On February 18, 2026, President & Chief Financial Officer Horn David R. sold 7,743 shares of Seer Inc.’s Class A common stock at $1.99 per share, a move driven by tax obligations tied to recently vested restricted stock units (RSUs). The sale left Horn holding 501,262 shares—just under 0.44 % of the outstanding equity—after the transaction. While the trade amount ($15,400) is modest relative to Seer’s $115 million market cap, it reflects the CFO’s routine exercise of RSU-related liquidity needs rather than a bearish signal.

What This Means for Investors

The CFO’s sale follows a pattern of disciplined equity accumulation in early February. In the week prior, Horn purchased 79,000 shares and 119,000 option‑right shares on February 3, bringing his holdings to roughly 509,000 shares. The net effect is a small net increase in ownership, suggesting confidence in the company’s growth trajectory. For shareholders, this continuity in insider holding can be reassuring, especially amid a sector where cash‑constrained biotech firms often see insiders liquidating significant stakes. Moreover, the timing—just after a 8 % weekly gain and a positive market sentiment score (+46)—indicates that the CFO is comfortable with the stock’s upward trajectory and the company’s upcoming health‑care conference announcements.

Broader Insider Landscape

Seer’s top executive, CEO Omid Farokhzad, has executed two significant sales on February 18, divesting 24,385 shares at the same price, while maintaining a large block of 3.35 million shares. Farokhzad’s activity, coupled with Horn’s modest net buy, paints a picture of a leadership team that balances liquidity needs with long‑term commitment. Compared with other insiders (e.g., Ro Isaac, Roelofs, MCGUIRE) who have primarily purchased shares, Seer’s insider base appears cohesive and growth‑oriented.

Profile of Horn David R.

Horn’s trading history shows a preference for option‑right purchases ahead of share acquisitions. The February 3 trades—119,000 option‑right shares and 79,000 shares—illustrate a strategy that leverages RSU vesting windows to secure favorable pricing and minimize dilution. His total holdings post‑transaction (~0.44 %) are modest but steady, and the recent sale aligns with typical tax‑planning behavior for RSU holders. Horn’s consistent buying pattern suggests he views Seer’s nanoparticle‑assay platform as a long‑term value driver, particularly as the company prepares for the TD Cowen conference and seeks to expand its customer base in the U.S. healthcare market.

Implications for Seer’s Future

With a negative P/E ratio of –1.48, Seer remains in a developmental phase where earnings are yet to materialize. Insider activity that demonstrates continued ownership—especially from the CFO—can help maintain investor confidence during periods of volatility. The recent positive buzz (85.81 %) and strong weekly price move reinforce the narrative that market participants are watching Seer’s product pipeline and conference disclosures closely. For investors, Horn’s balanced approach to liquidity and equity retention suggests that the company’s leadership is poised to navigate the next funding cycle while keeping shareholders’ interests aligned.